Clinical Trial Update: A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SB3 biosimilar to Herceptin in HER2-positive breast cancer; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• SB3 (trastuzumab biosimilar)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: HER2 Positive Early or Locally Advanced Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-10-24